Anika Therapeutics, Inc.
ANIKNASDAQHealthcare● Active
$14.60
+$0.12(+0.83%)
Market Cap$194262110
P/E Ratio—
52W High$16.24
52W Low$7.87
Anika Therapeutics, Inc. (ANIK) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ANIK · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: Apr 29, 2026EPS Actual
$0.27
Est. -$0.07 · +485.7%
Revenue
$0.03B
Est. $0.03B · +5.2%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
Apr 29, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 4-Quarter EPS Beat Streak
ANIK reports quarterly as a NASDAQ-listed Medical - Devices company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.21
Rev. $0.66B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.21
Rev. Est.$0.66B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Jul 29, 2026 | $0.03 | — | — | — | $0.03B | — |
| ▲ Q2 FY2026 | Apr 29, 2026 | -$0.07 | $0.27 | +485.7% | $0.03B | $0.03B | +5.2% |
| ▲ Q1 FY2026 | Feb 26, 2026 | -$0.13 | $0.31 | +348.0% | $0.03B | $0.03B | +6.0% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.02 | $0.04 | +100.0% | $0.03B | $0.03B | +0.1% |
| — Q3 FY2025 | Jul 30, 2025 | -$0.13 | -$0.13 | +0.0% | $0.03B | $0.03B | +2.5% |
| ▼ Q2 FY2025 | May 9, 2025 | $0.09 | -$0.06 | -166.7% | $0.03B | $0.03B | -6.8% |
| ▼ Q1 FY2025 | Mar 12, 2025 | -$0.01 | -$0.03 | -200.0% | $-0.00B | $0.03B | -104.6% |
| ▼ Q4 FY2024 | Oct 31, 2024 | $0.30 | -$0.25 | -183.3% | $0.04B | $0.03B | +33.6% |
Q3 FY2026
Jul 29, 2026
EPS Actual
—
EPS Est.
$0.03
EPS Surpr.
—
Revenue
—
Q2 FY2026
Apr 29, 2026Beat
EPS Actual
$0.27
EPS Est.
-$0.07
EPS Surpr.
+485.7%
Revenue
$0.03B
Q1 FY2026
Feb 26, 2026Beat
EPS Actual
$0.31
EPS Est.
-$0.13
EPS Surpr.
+348.0%
Revenue
$0.03B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$0.04
EPS Est.
$0.02
EPS Surpr.
+100.0%
Revenue
$0.03B
Q3 FY2025
Jul 30, 2025
EPS Actual
-$0.13
EPS Est.
-$0.13
EPS Surpr.
+0.0%
Revenue
$0.03B
Q2 FY2025
May 9, 2025Miss
EPS Actual
-$0.06
EPS Est.
$0.09
EPS Surpr.
-166.7%
Revenue
$0.03B
Q1 FY2025
Mar 12, 2025Miss
EPS Actual
-$0.03
EPS Est.
-$0.01
EPS Surpr.
-200.0%
Revenue
$-0.00B
Q4 FY2024
Oct 31, 2024Miss
EPS Actual
-$0.25
EPS Est.
$0.30
EPS Surpr.
-183.3%
Revenue
$0.04B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.07 | $0.07 | $0.08 | 1 |
| Q3 FY2027 | $0.05 | $0.05 | $0.05 | 1 |
| Q2 FY2027 | $0.04 | $0.04 | $0.04 | 1 |
| Q1 FY2027 | $0.01 | $0.01 | $0.01 | 1 |
| Q4 FY2026 | $0.01 | $0.01 | $0.02 | 1 |
| Q3 FY2026 | $-0.01 | $-0.01 | $-0.00 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | Apr 29, 2026 | +485.7% | $15.26 | $12.39 | -18.81% |
| ▲ Q1 FY2026 | Feb 26, 2026 | +348.0% | $10.94 | $12.79 | +16.91% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +100.0% | $9.63 | $9.85 | +2.28% |
| ▲ Q3 FY2025 | Jul 30, 2025 | +0.0% | $11.16 | $8.10 | -27.42% |
| ▼ Q2 FY2025 | May 9, 2025 | -166.7% | $14.74 | $11.64 | -21.03% |
| ▼ Q1 FY2025 | Mar 12, 2025 | -200.0% | $16.79 | $17.11 | +1.91% |
| ▼ Q4 FY2024 | Oct 31, 2024 | -183.3% | $24.68 | $17.11 | -30.67% |
| ▼ Q3 FY2024 | Aug 8, 2024 | -26.1% | $25.95 | $25.68 | -1.04% |
Q2 FY2026-18.81%
Report Date
Apr 29, 2026
EPS Beat/Miss
+485.7%
Price Before
$15.26
Price After
$12.39
Q1 FY2026+16.91%
Report Date
Feb 26, 2026
EPS Beat/Miss
+348.0%
Price Before
$10.94
Price After
$12.79
Q4 FY2025+2.28%
Report Date
Nov 5, 2025
EPS Beat/Miss
+100.0%
Price Before
$9.63
Price After
$9.85
Q3 FY2025-27.42%
Report Date
Jul 30, 2025
EPS Beat/Miss
+0.0%
Price Before
$11.16
Price After
$8.10
Q2 FY2025-21.03%
Report Date
May 9, 2025
EPS Beat/Miss
-166.7%
Price Before
$14.74
Price After
$11.64
Q1 FY2025+1.91%
Report Date
Mar 12, 2025
EPS Beat/Miss
-200.0%
Price Before
$16.79
Price After
$17.11
Q4 FY2024-30.67%
Report Date
Oct 31, 2024
EPS Beat/Miss
-183.3%
Price Before
$24.68
Price After
$17.11
Q3 FY2024-1.04%
Report Date
Aug 8, 2024
EPS Beat/Miss
-26.1%
Price Before
$25.95
Price After
$25.68
Avg Beat Reaction-6.76%
Avg Miss Reaction-12.71%
Beat Rate4 / 8 quarters
Largest Move-30.67% (Q4 FY2024)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ANIK ends December
Anika Therapeutics, Inc. (ANIK) most recently reported earnings on April 29, 2026 for Q2 FY2026, posting EPS of $0.27 — beating the analyst consensus of $-0.07 by +485.7%. ANIK has beaten EPS estimates for 4 consecutive quarters. The next ANIK earnings date is expected around September 1, 2026.
Each quarter, investors track ANIK earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ANIK revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ANIK's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ANIK earnings · 5 questionsAnika Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ANIK typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ANIK historically reports after market close (AMC).
ANIK earnings datewhen is ANIK earningsANIK next earnings datewhen does ANIK report earningsANIK earnings calendar
▸ Source: FMP · Anika Therapeutics, Inc. SEC filings · US GAAP · Anika Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026